Eli Lilly & Co. (LLY)

108.34
1.25 1.17
NYSE : Health Technology
Prev Close 107.09
Open 107.83
Day Low/High 107.24 / 108.48
52 Wk Low/High 88.17 / 132.13
Volume 3.05M
Avg Volume 4.41M
Exchange NYSE
Shares Outstanding 970.83M
Market Cap 105.65B
EPS 3.10
P/E Ratio 41.85
Div & Yield 2.58 (2.23%)

Latest News

Bristol-Myers Squibb, Eli Lily, DuPont: 'Mad Money' Lightning Round

Bristol-Myers Squibb, Eli Lily, DuPont: 'Mad Money' Lightning Round

Jim Cramer weighs in on Bristol-Myers Squibb, Eli Lily, DuPont, Marvell Technology, General Motors, Kraft Heinz, Maxar Technologies, and more.

Lilly Presents New Findings On Stigma Faced By People With Migraine Based On Interim Results From The OVERCOME Observational Study

Lilly Presents New Findings On Stigma Faced By People With Migraine Based On Interim Results From The OVERCOME Observational Study

-Data from OVERCOME shed new light on migraine stigma by examining attitudes through the eyes of people who have not been diagnosed with migraine[1]

Lilly's OVERCOME Observational Study Reveals Inconsistent And Sub-Optimal Treatment Landscape For Migraine

Lilly's OVERCOME Observational Study Reveals Inconsistent And Sub-Optimal Treatment Landscape For Migraine

-Data from OVERCOME showed that inconsistent care patterns, including high use of emergency department/urgent care settings, may be contributing to misdiagnosis, sub-optimal treatment and increased healthcare utilization(1)

AHS 2019: Post-Hoc Analyses Of Phase 3 Pivotal Studies Of Emgality® (galcanezumab-gnlm) Show Improvements In Daily Functioning And Reductions In Disability In Patients With Chronic And Episodic Migraine

AHS 2019: Post-Hoc Analyses Of Phase 3 Pivotal Studies Of Emgality® (galcanezumab-gnlm) Show Improvements In Daily Functioning And Reductions In Disability In Patients With Chronic And Episodic Migraine

-Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue(1)

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

Lilly Announces Changes In Senior Leadership

Lilly Announces Changes In Senior Leadership

Mike Harrington, senior vice president and general counsel, to retire at year end

New England Journal Of Medicine Publishes Positive Phase 3 Data For Emgality® (galcanezumab-gnlm) In Episodic Cluster Headache

New England Journal Of Medicine Publishes Positive Phase 3 Data For Emgality® (galcanezumab-gnlm) In Episodic Cluster Headache

INDIANAPOLIS, July 11, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality ® (galcanezumab-gnlm) for the treatment of episodic cluster...

Lilly Announces Upcoming Presentation Of New Data Indicating Rise In Opioid Use For Migraine Treatment

Lilly Announces Upcoming Presentation Of New Data Indicating Rise In Opioid Use For Migraine Treatment

-Findings showed that nearly 1 in 5 people with migraine (19%) are currently using opioids to treat their disease, up from 16 percent in 2009(1,2)

Lilly Confirms Date And Conference Call For Second-Quarter 2019 Financial Results Announcement

Lilly Confirms Date And Conference Call For Second-Quarter 2019 Financial Results Announcement

INDIANAPOLIS, July 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019.

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

Lilly's AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity® (dulaglutide) Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes

Lilly's AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity® (dulaglutide) Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes

INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of superiority, significantly reducing A1C from baseline in people...

U.S. FDA Grants Fast Track Designation To Empagliflozin For The Treatment Of Chronic Heart Failure

U.S. FDA Grants Fast Track Designation To Empagliflozin For The Treatment Of Chronic Heart Failure

- Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

Lilly Declares Third-Quarter 2019 Dividend

Lilly Declares Third-Quarter 2019 Dividend

INDIANAPOLIS, June 19, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

Lilly Presents Positive Results For Taltz® (ixekizumab) Vs. Humira® (adalimumab) In A Head-to-Head (SPIRIT-H2H) Superiority Study In Patients With Active Psoriatic Arthritis At The European Congress Of Rheumatology

Lilly Presents Positive Results For Taltz® (ixekizumab) Vs. Humira® (adalimumab) In A Head-to-Head (SPIRIT-H2H) Superiority Study In Patients With Active Psoriatic Arthritis At The European Congress Of Rheumatology

INDIANAPOLIS, June 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA) as a...

Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish

Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish

Let's step back and look at the bigger picture through charts and indicators.

Good Value or Value Trap?: Cramer's 'Mad Money' Recap (Wednesday 6/12/19)

Good Value or Value Trap?: Cramer's 'Mad Money' Recap (Wednesday 6/12/19)

Jim Cramer says spotting the bottom is really tough; and if you're too early, you'll get hit hard.

Jim Cramer: A Tale of Two Stocks

Jim Cramer: A Tale of Two Stocks

I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

Lilly To Present 5-Year Sustained Efficacy And Safety Results For Taltz® (ixekizumab) In Patients With Plaque Psoriasis At The World Congress Of Dermatology

Lilly To Present 5-Year Sustained Efficacy And Safety Results For Taltz® (ixekizumab) In Patients With Plaque Psoriasis At The World Congress Of Dermatology

INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz ® (ixekizumab).

Detailed Findings From CAROLINA® Outcome Trial Support Long-term Cardiovascular Safety Profile Of Tradjenta®

Detailed Findings From CAROLINA® Outcome Trial Support Long-term Cardiovascular Safety Profile Of Tradjenta®

- CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor

New Analysis Shows Cardiorenal Risk Reductions Of Jardiance® Are Consistent In Adults With Type 2 Diabetes, Cardiovascular Disease And Kidney Disease Without Overt Proteinuria

New Analysis Shows Cardiorenal Risk Reductions Of Jardiance® Are Consistent In Adults With Type 2 Diabetes, Cardiovascular Disease And Kidney Disease Without Overt Proteinuria

- Findings from an EMPA-REG OUTCOME® post-hoc analysis of adults with chronic kidney disease without overt proteinuria presented at American Diabetes Association's 79th Scientific Sessions®

Thor Industries and Eli Lilly Offer a Tale of Two Stocks

Thor Industries and Eli Lilly Offer a Tale of Two Stocks

The charts of the maker of recreational vehicles are bearish, while the drugmaker appears to be a buy

Trulicity® (dulaglutide) Significantly Reduced Major Cardiovascular Events For Broad Range Of People With Type 2 Diabetes

Trulicity® (dulaglutide) Significantly Reduced Major Cardiovascular Events For Broad Range Of People With Type 2 Diabetes

REWIND data showed a consistent effect in people with and without established cardiovascular disease

TheStreet Quant Rating: C+ (Hold)